berotralstat

oral plasma kallikrein inhibitor

Also Known As:

1-(3-(aminomethyl)phenyl)-N-(5-((R)-(3-cyanophenyl)((cyclopropylmethyl)amino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide; 1H-pyrazole-5-carboxamide, 1-(3-(aminomethyl)phenyl)-N-(5-((R)-(3-cyanophenyl)((cyclopropylmethyl); BCX-7353; BCX7353

Networked: 25 relevant articles (2 outcomes, 11 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - berotralstat: 25

Experts

1.	Cornpropst, Melanie: 5 articles (01/2022 - 01/2018)
2.	Sheridan, William P: 5 articles (01/2022 - 01/2021)
3.	Aygören-Pürsün, Emel: 4 articles (06/2021 - 01/2018)
4.	Best, Jessica M: 4 articles (06/2021 - 01/2021)
5.	Murray, Sharon C: 4 articles (06/2021 - 01/2021)
6.	Nagy, Eniko: 4 articles (06/2021 - 01/2021)
7.	Craig, Timothy: 3 articles (02/2022 - 12/2019)
8.	Dobo, Sylvia M: 3 articles (06/2021 - 01/2021)
9.	Farkas, Henriette: 3 articles (06/2021 - 01/2018)
10.	Iocca, Heather A: 3 articles (06/2021 - 01/2021)

Related Diseases

1.	Hereditary Angioedemas 06/01/2021 - "Long-term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APeX-S study." 01/01/2021 - "Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial." 01/01/2021 - "Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial." 11/02/2023 - "A Retrospective Analysis of Long-Term Prophylaxis with Berotralstat in Patients with Hereditary Angioedema and Acquired C1-Inhibitor Deficiency-Real-World Data." 11/01/2023 - "Evaluation of the safety and effectiveness of berotralstat for patients with hereditary angioedema: Report of six cases."
2.	Angioedema 11/02/2023 - "Patients with HAE, HAE-nC1-INH, and AAE-C1-INH treated with Berotralstat showed reduced angioedema attacks and improved AE-QoL and AECT scores." 02/01/2022 - "Preclinical and phase I studies showed promising efficacy and safety, and several multicenter international Angioedema Prophylaxis (APeX) phase II and III trials have since been initiated to further evaluate berotralstat. " 01/01/2018 - "In this international, three-part, dose-ranging, placebo-controlled trial, we evaluated four doses of BCX7353 (62.5 mg, 125 mg, 250 mg, and 350 mg once daily) for the prevention of angioedema attacks over a 28-day period. " 11/01/2023 - "Similarly, meaningful patient-reported improvements from both Angioedema Quality of Life Questionnaire and Treatment Satisfaction Questionnaire for Medication scores were achieved, with a sustained benefit shown over the berotralstat treatment period. " 01/01/2021 - "Clinical studies demonstrated that oral administration of Berotralstat to HAE type I or type II patients at a dose of 150 mg once daily showed a reduction of HAE attack rate and clinically significant change in angioedema quality of life score. "
3.	Abdominal Pain (Pain, Abdominal) 01/01/2021 - "The most frequent treatment-emergent adverse events that occurred more with berotralstat than with placebo were abdominal pain, vomiting, diarrhea, and back pain. " 11/01/2023 - "Berotralstat was generally well tolerated, with nasopharyngitis (21%), upper respiratory tract infection (15%), nausea (15%), diarrhea (15%), and abdominal pain (10%) being the most common adverse events occurring in ≥10% of the total subset. " 01/01/2021 - "The most frequently reported treatment-emergent adverse events (TEAEs) in berotralstat-treated patients (n = 13) were nasopharyngitis (n = 4, 31%), abdominal pain, cough, diarrhea, and pyrexia (n = 2 each, 15%). "
4.	Diarrhea 01/01/2021 - "The most frequent treatment-emergent adverse events that occurred more with berotralstat than with placebo were abdominal pain, vomiting, diarrhea, and back pain. " 11/01/2023 - "Berotralstat was generally well tolerated, with nasopharyngitis (21%), upper respiratory tract infection (15%), nausea (15%), diarrhea (15%), and abdominal pain (10%) being the most common adverse events occurring in ≥10% of the total subset. " 01/01/2021 - "The most frequently reported treatment-emergent adverse events (TEAEs) in berotralstat-treated patients (n = 13) were nasopharyngitis (n = 4, 31%), abdominal pain, cough, diarrhea, and pyrexia (n = 2 each, 15%). "
5.	Nasopharyngitis 11/01/2023 - "Berotralstat was generally well tolerated, with nasopharyngitis (21%), upper respiratory tract infection (15%), nausea (15%), diarrhea (15%), and abdominal pain (10%) being the most common adverse events occurring in ≥10% of the total subset. " 01/01/2021 - "The most frequently reported treatment-emergent adverse events (TEAEs) in berotralstat-treated patients (n = 13) were nasopharyngitis (n = 4, 31%), abdominal pain, cough, diarrhea, and pyrexia (n = 2 each, 15%). "

Related Drugs and Biologics

1.	Plasma Kallikrein
2.	berotralstat
3.	Kallikreins (Kallikrein)
4.	lanadelumab
5.	Androgens
6.	Complement C1 Inhibitor Protein (C1 Esterase Inhibitor)
7.	acivicin (AT 125)

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration
3.	Injections